TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
The American Geriatrics Society has published a case-based framework to help clinicians prescribe obesity medications, including incretin therapies, with older adults’ health and goals in view. It calls for assessment of function, nutrition and cognition, and attention to risks such as muscle loss, frailty, malnutrition and dehydration.
The American Geriatrics Society (AGS) has released a case-based framework to help clinicians prescribe obesity medications safely and in a patient-centered way for older adults. The paper, published in the Journal of the American Geriatrics Society, adapts the AGS’s Geriatrics 5Ms approach to incretin therapies and emphasizes evaluating function, nutrition and cognition before treatment.
The framework is organized around clinical cases and addresses obesity medications, including GLP-1 medicines that act through gut-derived hormonal pathways. The authors say these therapies may offer benefits for weight management, blood sugar control and other health conditions. However, they also point out that older adults are underrepresented in clinical trials, leaving clinicians with less evidence specific to this age group.
The paper highlights age-related considerations that can shape prescribing decisions: frailty and sarcopenia, the possibility of losing lean muscle, and risks of malnutrition and dehydration. It recommends assessing functional status, nutritional adequacy and cognitive impairment before starting treatment, rather than judging suitability on weight or a medication’s potential benefits alone.
According to the report, the authors recommend pairing medication with resistance training and adequate dietary protein. They say care may call for a team that includes a registered dietitian, physical therapist, fitness trainer and behavioral health professional. The paper was developed by the AGS Healthy Aging Special Interest Group. Its lead author is Elias M. Wisdom; the article’s DOI is 10.1111/jgs.70769.
Balancing Weight Loss With Function
The framework matters because weight reduction is not the only consideration for an older person considering obesity medication. Muscle strength, mobility, nutritional status and daily function can affect independence and health, so medication choices and monitoring may need to account for outcomes beyond the number on a scale.
By organizing care around the 5Ms—Mind, Mobility, Medications, Multicomplexity and Matters Most—the paper gives clinicians a structure for discussing cognitive health, movement, other medicines, complex conditions and the patient’s own priorities. This may help make conversations about treatment more individualized, while the framework does not establish that a particular medication is appropriate for every older adult.
The recommendations also point to the practical work that can accompany a prescription. Checking food intake, hydration and ability to exercise, then coordinating supportive care, can help clinicians address risks the authors identify. The report describes a prescribing framework, not evidence that these steps guarantee a particular outcome.
Products Worth Considering
Levoit Core 600S-P Smart Air Purifier for Large Rooms
BowFlex Results Series SelectTech Adjustable Dumbbells, Pair
Bowflex SelectTech 840 Adjustable Kettlebell
As an affiliate, we earn on qualifying purchases.
Applying the Geriatrics 5Ms
The AGS’s Geriatrics 5Ms Framework provides the organizing structure for the new paper. The five domains are Mind, Mobility, Medications, Multicomplexity and Matters Most. In this report, the authors apply that model to incretin therapy in older adults through a series of cases intended to make the considerations usable in clinical practice.
The paper appears as interest in obesity medications grows, but the source report says older adults have been underrepresented in clinical trials. That evidence gap is one reason the authors emphasize assessment and individualized decisions. The article does not report a new clinical trial or compare the effectiveness of different drugs; it sets out considerations for clinicians rather than issuing a universal treatment rule.
“Older adults are underrepresented in clinical trials.”
— Medical Xpress report summarizing the paper
Evidence Gaps in Older Patients
The report does not provide new trial results, quantify how often the risks it discusses occur, or establish which older patients benefit most from a specific medicine. It also does not give a single prescribing protocol that applies to every patient. How well the framework improves outcomes is not established by the material provided.
Details such as how clinicians should weigh individual risks against expected benefits, which monitoring schedules to use, and how recommendations may differ among medications are not specified in the report. The underlying paper may contain further discussion, but those specifics are not available in the supplied source summary. The extent of the evidence gap for particular drugs and patient groups also remains unclear.
How Clinicians May Use the Framework
The paper is available in the Journal of the American Geriatrics Society and offers clinicians a case-based structure to apply when discussing obesity medications with older patients. In practice, the approach calls for pretreatment assessment of function, nutrition and cognition, followed by consideration of supportive measures such as resistance exercise and adequate protein intake.
The supplied report does not identify a formal implementation timeline, planned guideline update or follow-up study. Further research involving more older adults would help clarify medication-specific benefits and risks in this population. For now, the published framework sets out considerations for clinical decision-making; it does not replace an individual assessment by a qualified health professional.
Key Questions
What did the American Geriatrics Society publish?
It published a case-based framework for clinicians considering obesity medications for older adults, using the AGS Geriatrics 5Ms approach.
Which medicines does the framework address?
The paper discusses obesity medications, including incretin therapies such as GLP-1 medicines. The source summary does not provide a drug-by-drug comparison.
What should clinicians assess before treatment?
The report says the authors recommend assessing functional status, nutritional adequacy and cognitive impairment, while considering frailty, sarcopenia, lean muscle loss, malnutrition and dehydration.
Does the framework recommend supportive measures?
Yes. The authors recommend pairing treatment with resistance training and adequate dietary protein. They say some patients may benefit from coordinated support involving professionals such as dietitians and physical therapists.
Does the paper prove these medicines are safe for all older adults?
No. The report describes a prescribing framework, not proof of safety or benefit for every older adult. It also notes that older adults are underrepresented in clinical trials; treatment decisions require individual clinical assessment.
Source: medicalxpress.com
